Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination…
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult…
Read More...
Read More...
